Identification of PLAC1 as a prognostic biomarker and molecular target in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is a common clinical tumor of the urinary system. The lack of effective diagnostic and treatment options poses a serious challenge to clinical treatment. Therefore, identifying effective molecular targets has become one of the potential means to treat this disease. Firstly, the analysis of the TCGA database found that PLAC1 was abnormally highly expressed in ccRCC and was negatively correlated with patient prognosis. Western blotting and immunofluorescence experiments further verified that PLAC1 was highly expressed in ccRCC patients, and knockdown of PLAC1 inhibited the development of ccRCC in vitro. Last, high-throughput virtual screening technology (HTVS) was performed to identify two molecular inhibitors ，AmB and Cana, which were able to reduce the expression of PLAC1 and inhibited the progression of ccRCC. In conclusion, the current investigation indicated that the PLAC1 could serve as a prognostic biomarker, and AmB and Cana inhibit the progression of ccRCC by reducing PLAC1, making it a potential therapeutic option for ccRCC.